



**Results and Discussion.** – Compound **1**, obtained as an optically active, yellowish oil ( $[\alpha]_D^{29} = -20.0$  ( $c = 0.5$ , MeOH), had the molecular formula  $C_{21}H_{31}NO_{10}$ , as determined by HR-ESI-MS ( $m/z$  480.1836 ( $[M + Na]^+$ ; calc. 480.1840). Its UV spectrum showed bands at 202 and 287 nm, and the IR spectrum displayed absorption bands for OH (3371),  $Me_2CH$  (2929), and C=O (1731, 1689  $cm^{-1}$ ) moieties.

In the NMR spectra of **1** (Table 1), the signals at  $\delta(H)$  4.23 ( $d, J = 8.0$  Hz) and  $\delta(C)$  105.60 ( $d$ ), 69.89 ( $d$ ), 74.10 ( $d$ ), 76.50 ( $d$ ), 76.84 ( $d$ ), and 61.02 ( $t$ ) indicated a  $\beta$ -glucopyranosyl (Glc) moiety [19], D-configuration being assumed on biogenetic grounds. The  $^1H$ - and  $^{13}C$ -NMR (DEPT) spectra indicated five quaternary C-atoms, nine CH, four  $CH_2$ , and three Me groups. In the  $^1H$ -NMR spectrum, there were typical signals for three Me groups at  $\delta(H)$  1.21 ( $d, J = 6.8$ ), 0.80 ( $d, J = 6.8$ ), and 0.74 ( $d, J = 6.8$  Hz), as well as signals for an olefin at  $\delta(H)$  7.24, 6.49 ( $2d, J = 2.4$  Hz each,  $2 \times 1$  H). In the  $^{13}C$ -NMR spectrum, there were resonances for two C=O functions [ $\delta(C)$  189.84 ( $\alpha, \beta$ -unsaturated C=O group); 172.81 (ester C=O group)], two C=C bonds [ $\delta(C)$  129.4, 123.4, 117.4, 116.6]; and eight oxygenated C-atoms [ $\delta(C)$  82.6, 82.5, 76.8, 76.5, 74.1, 69.9, 61.0, 57.6]. The  $^1H$ - and  $^{13}C$ -NMR data of **1** were fully assigned by means of  $^1H, ^1H$ -COSY, HMQC, and HMBC experiments (Fig. 1).

The HMBC correlations of both H–C(5)<sup>3</sup>) ( $\delta(H)$  4.26) and H–C(6) ( $\delta(H)$  2.92) with C(7) ( $\delta(C)$  189.84), between H–C(2) ( $\delta(H)$  6.49) and both C(1) ( $\delta(C)$  117.38)

Table 1.  $^1H$ -,  $^{13}C$ -, and 2D-NMR Data of **1**. At 400/100 MHz, resp.;  $\delta$  in ppm,  $J$  in Hz. Arbitrary atom numbering. Asterisks (\*) mark overlapping signals.

Position	$\delta(H)$	$\delta(C)$	COSY	HMBC
1		117.38		2, 3, 9
2	6.49 ( $d, J = 2.4$ )	116.64	3	3, 9
3	7.24 ( $d, J = 2.4$ )	123.40	2	2
5	4.26 ( $t, J = 6.0$ )	42.13	6	6
6	2.92 ( $t, J = 6.0$ )	39.30	5	5
7		189.84		5, 6
8		129.40		2, 3, 9
9	5.13 ( $s$ )	57.61		2
1'		172.81		9
2'		82.55		3', 5', 6', 7'
3'	3.76 ( $q, J = 6.8$ )	82.49	4'	4', 1''
4'	1.21 ( $d, J = 6.8$ )	16.98	3'	3'
5'	2.03–2.06 ( $m$ )	31.27	6', 7'	6', 7'
6'	0.80 ( $d, J = 6.8$ )	15.86	5'	5', 7'
7'	0.74 ( $d, J = 6.8$ )	17.67	5'	5', 6'
1''	4.23 ( $d, J = 8.0$ )	105.60		3'
2''	2.90–3.10 ( $m$ )*	69.89		
3''	2.90–3.10 ( $m$ )*	74.10		
4''	2.90–3.10 ( $m$ )*	76.50		
5''	2.90–3.10 ( $m$ )*	76.84		
6''	3.62 ( $dd, J = 3.2, 6.0$ )	61.02		
	3.41 ( $dd, J = 3.2, 6.0$ )			

<sup>3</sup>) Arbitrary atom numbering. For systematic names of **1** and **2**, see *Exper. Part*.




Fig. 1. Selected COSY and HMBC correlations of **1**

and C(3) ( $\delta(\text{C})$  123.40), and between H–C(3) ( $\delta(\text{H})$  7.24) and both C(1) ( $\delta(\text{C})$  117.38) and C(2) ( $\delta(\text{C})$  116.64) suggested a partly hydrated pyrrolizine framework. Furthermore, HMBC correlations between H–C(9) ( $\delta(\text{H})$  5.13) and C(1) ( $\delta(\text{C})$  117.38), C(1') ( $\delta(\text{C})$  172.81), C(2) ( $\delta(\text{C})$  116.64), and C(8) ( $\delta(\text{C})$  129.40), as well as of H–C(3') ( $\delta(\text{H})$  3.76) and H–C(5') ( $\delta(\text{H})$  2.04) with C(2') ( $\delta(\text{C})$  116.64) indicated that an oxygenated CH<sub>2</sub> group (CH<sub>2</sub>(9)) was connected to the pyrrolizine unit at C(1), whereas C(3') and C(5') were attached to C(2'). The 3'-attachment of the GlcO moiety in **1** was derived from HMBC correlations between H–C(3') ( $\delta(\text{H})$  3.76) and the anomeric C(1'') resonance ( $\delta(\text{C})$  105.60), as well as from a correlation between H–C(1'') ( $\delta(\text{H})$  4.23) and C(3') ( $\delta(\text{C})$  82.49). In comparison with a structurally related compound previously reported in the literature [20], we found that C(3') was shifted downfield by *ca.* 12 ppm, which further confirmed that the Glc unit was connected to the 3'-O-atom of the aglycone.

From the above data, the structure of compound **1** was, thus, elucidated as (2,3-dihydro-1-oxo-1*H*-pyrrolo[1,2-*a*]pyrrol-7-yl)methyl (2*S*\*,3*S*\*)-3-[( $\beta$ -D-glucopyranosyl)-oxy]-2-hydroxy-2-(1-methylethyl)butanoate.


Compound **2**, isolated as a yellowish amorphous powder, showed the [*M* + 1]<sup>+</sup> peak at *m/z* 219 by EI-MS, indicating the molecular formula C<sub>8</sub>H<sub>11</sub>NO<sub>4</sub>. The IR spectrum (KBr) showed absorption bands for OH (3354), COOH (1708), and aromatic (1510 cm<sup>-1</sup>) moieties.

The <sup>1</sup>H- and <sup>13</sup>C-NMR (DEPT) spectra of **2** (Table 2) showed one MeO group, four CH moieties, and six quaternary C-atoms. In the <sup>1</sup>H-NMR spectrum, the MeO group appeared at  $\delta(\text{H})$  3.99 (*s*), together with olefinic signals at  $\delta(\text{H})$  6.64 (*s*, 1 H), 7.61 (*dd*, *J* = 2.8, 7.2, 1 H), 7.31 (*br. d*, *J* = 7.2), and 7.28 (*br. d*, *J* = 7.2 Hz). In the <sup>13</sup>C-NMR spectrum, there were resonances for two C=O functions [ $\delta(\text{C})$  176.9 (COOH), 163.5 (lactam C=O)], four C=C bonds [ $\delta(\text{C})$  109.8, 138.2, 115.0, 124.1, 111.8, 148.7, 130.1, 128.0], and one oxygenated C-atom [ $\delta(\text{C})$  56.4]. By comparison of the NMR-spectroscopic data of **1** with those of related compounds [21], a structure based on a quinolin-2-one was inferred. The HMBC correlations (Fig. 2) between the MeO H-atoms ( $\delta(\text{H})$  3.99) and C(8) ( $\delta(\text{C})$  148.7), and of both H–C(5) ( $\delta(\text{H})$  7.61) and H–C(3) ( $\delta(\text{H})$  6.64) with C(12) ( $\delta(\text{C})$  176.9) showed that the COOH and MeO groups were attached at C(8) and C(4), respectively.

From above data, the structure of compound **2** was, thus, elucidated as 1,2-dihydro-8-methoxy-2-oxoquinoline-4-carboxylic acid.

Table 2.  $^1\text{H}$ -,  $^{13}\text{C}$ -, and HMBC Data of **2**. At 400/100 MHz, resp.;  $\delta$  in ppm,  $J$  in Hz. Arbitrary atom numbering.

Position	$\delta(\text{H})$	$\delta(\text{C})$	HMBC
2		163.5	3
3	6.64 (s)	109.8	
4		138.2	3
5	7.61 (dd, $J=2.8, 7.2$ )	115.0	3, 7, 6
6	7.31 (br. d, $J=7.2$ )	124.1	7, 5
7	7.28 (br. d, $J=7.2$ )	111.8	5, 6
8		148.7	5, 6, 7, 11
9		130.1	3, 6
10		128.0	5, 7
MeO	3.99 (s)	56.4	
COOH		176.9	3, 5

Fig. 2. Selected HMBC (H  $\rightarrow$  C) correlations of **2**

This work was supported by the *National Natural Science Foundation of China* (No. 20475057) and the *Natural Science Foundation of Gansu Province* (No. 3ZS051-A25-077).

#### Experimental Part

*General.* TLC: silica gel  $GF_{254}$  (10–40  $\mu\text{m}$ ; *Qingdao Marine Chemical Factory*). Column chromatography (CC): silica gel (200–300 mesh; *Qingdao*) or *HPD-100* resin (*Hebei, China*). Optical rotations: *Perkin-Elmer 341* polarimeter. UV Spectra: *Analytic Jena* apparatus;  $\lambda_{\text{max}}$  (log  $\epsilon$ ) in nm. IR spectra: *Nicolet NEXUS-670 FT-IR* spectrophotometer; in  $\text{cm}^{-1}$ . NMR Spectra: *Varian INOVA-400* spectrometer; in  $\text{CDCl}_3$  or  $(\text{D}_6)\text{DMSO}$  soln.;  $\delta$  in ppm rel. to  $\text{Me}_4\text{Si}$ ,  $J$  in Hz. HR-ESI-MS: *Bruker APEX-II* mass spectrometer; in  $m/z$ .

*Plant Material.* *C. gansuense* Y. L. LIU was collected in Weiyuan County, Gansu Province, P. R. China, and identified by adjunct Prof. *Ji Ma* (Faculty of Pharmacy, First Military Medical University of PLA, Guangzhou, P. R. China). A voucher specimen (No. 2001-03) was deposited at the Key Laboratory for Natural Medicine of Gansu Province.

*Extraction and Isolation.* The air-dried, ground whole plant of *C. gansuense* (2.5 kg) was extracted with 95% EtOH at r.t. ( $7 \times 24$  h). The solvent was removed under reduced pressure, the residue (160 g) was suspended in  $\text{H}_2\text{O}$  (1.0 l), extracted with petroleum ether (b.p. 60–90 $^\circ$ ;  $8 \times 1$  l), AcOEt ( $4 \times 750$  ml), and BuOH ( $12 \times 1$  l).

The PE-soluble fraction (64 g) was subjected to CC ( $\text{SiO}_2$ ; PE/AcOEt 40:1  $\rightarrow$  1:1) to afford five main fractions (*Fr. A–E*). *Fr. B* was further separated into three subfractions (*Fr. B1–B3*) by CC ( $\text{SiO}_2$ ; petroleum ether/ $\text{CHCl}_3$  5:1). *Fr. B1* was further purified by CC ( $\text{SiO}_2$ ; petroleum ether/AcOEt 10:1) to afford *trans*-phytol (6 mg). *Fr. B2* was repeatedly subjected to CC ( $\text{SiO}_2$ ; cyclohexane/ $\text{Et}_2\text{O}$  25:1) to afford crude stigmast-4-en-3-one, which was purified by CC ( $\text{SiO}_2$ ;  $\text{CHCl}_3$ /AcOEt 30:1; 8 mg of pure product), together with a mixture of lupa-12,20(29)-dien-3 $\beta$ -ol and 18 $\alpha$ H-ursa-12,20(30)-dien-3 $\alpha$ -ol, which was further purified by CC ( $\text{SiO}_2$ ; petroleum ether/AcOEt 10:1) to afford 8 mg of the mixed products. *Fr. C* was subjected to CC ( $\text{SiO}_2$ ; PE/acetone 15:1) to provide crude stigmast-5-ene-3 $\beta$ ,7 $\alpha$ -diol

and  $\beta$ -sitosterol. They were purified by CC (SiO<sub>2</sub>; PE/acetone 10:1 and petroleum ether/AcOEt 18:1, resp.) to afford 7 and 15 mg of the pure compounds, resp. *Fr. D* was repeatedly chromatographed (SiO<sub>2</sub>; CHCl<sub>3</sub>/AcOEt 15:1) to afford stigmastan-3,6-dione (11 mg).

The AcOEt-soluble original fraction (6 g) was subjected to CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 10:1) to afford crude  $\beta$ -sitosterol-3-(6'-glyceryl)-D-glucopyranoside, which was further purified by CC (SiO<sub>2</sub>; AcOEt/MeOH 15:1) to yield the pure compound (10 mg).

The BuOH-soluble fraction and *Fr. E* (32 g) from the PE-soluble extract were combined and further separated by CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 8:1) into five fractions (*Fr. F1–F5*). *Fr. F1* was further chromatographed (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 6:1) to yield crude **2**, which was repeatedly subjected to CC (SiO<sub>2</sub>; AcOEt/MeOH 10:1) to afford 12 mg of pure material. *Fr. F2* was subjected to CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 10:1) to provide crude **1**, which was further purified by CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 10:1) to afford 15 mg of pure material. *Fr. F3* was subjected to CC (SiO<sub>2</sub>; AcOEt/MeOH 12:1) to give crude eugenylglucoside, which was further purified by CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 15:1) to give 12 mg of the pure compound. *Fr. F4* was chromatographed (SiO<sub>2</sub>; AcOEt/MeOH 12:1) to afford crude lariciresinol-9-*O*- $\beta$ -D-glucoside, which was further purified by CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/AcOEt/MeOH 6:4:1) to yield 30 mg of the pure material. *Fr. F5* was subjected to CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH/H<sub>2</sub>O 100:15:1) to give a mixture of 9-hydroxyguaiamonoepoxyignan-9-*O*- $\beta$ -D-glucoside and kaempferol-3-*O*- $\beta$ -D-glucopyranoside, the former of which was purified by CC (AcOEt/MeOH 10:1) to yield 20 mg of material. The latter (residual fraction after CC) was re-subjected to CC (SiO<sub>2</sub>; CHCl<sub>3</sub>/MeOH 4:1) to yield 5 mg of the pure material.

(2,3-Dihydro-1-oxo-1H-pyrrolo[1,2-a]pyrrol-7-yl)methyl (2S\*,3S\*)-3-[( $\beta$ -D-Glucopyranosyl)oxy]-2-hydroxy-2-(1-methylethyl)butanoate (**1**). Yellowish oil.  $[\alpha]_D^{20} = -20$  ( $c = 0.5$ , MeOH). UV (MeOH): 202 (4.57), 287 (4.17). IR (KBr): 3371, 2929, 1731, 1689, 1384, 1332, 1234, 1157, 1074, 1025, 763. <sup>1</sup>H- and <sup>13</sup>C-NMR: see Table 1. HR-ESI-MS: 480.1836 ( $[M + Na]^+$ , C<sub>21</sub>H<sub>31</sub>NaNO<sub>10</sub><sup>+</sup>; calc. 480.1840).

1,2-Dihydro-8-methoxy-2-oxoquinoline-4-carboxylic Acid (**2**). Yellowish, amorphous powder. IR (KBr): 3354, 2951, 2916, 2847, 1708, 1570, 1510, 1427, 1368, 1312, 1270, 1069, 868, 736. <sup>1</sup>H- and <sup>13</sup>C-NMR: see Table 2. EI-MS: 219 ( $[M + 1]^+$ , C<sub>8</sub>H<sub>12</sub>NO<sub>4</sub><sup>+</sup>).

Kaempferol-3-*O*- $\beta$ -D-glucopyranoside. Yellow needles (MeOH). M.p. 231–233°. IR (KBr): 3406, 1745, 1654, 1608, 1498, 1362, 1209, 1179, 1073. <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 8.03 (*d*,  $J = 8.4$ , 2 H); 6.87 (*dd*,  $J = 2.1$ , 8.7, 2 H); 6.41 (*d*,  $J = 1.6$ , 1 H); 6.19 (*d*,  $J = 1.2$ ); 5.44 (*d*,  $J = 7.2$ , 1 H); 3.71 (*dd*,  $J = 2.1$ , 11.7, 1 H); 3.50 (*dd*,  $J = 5.4$ , 11.7, 1 H); 3.40 (*dd*,  $J = 7.2$ , 10.0, 1 H); 3.40–3.25 (*m*, 2 H); 3.20 (*ddd*,  $J = 2.1$ , 5.1, 11.7, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 177.4; 165.1; 161.2; 156.5; 156.2; 133.2; 130.9; 120.9; 115.2; 103.8; 101.0; 99.0; 93.8; 77.5; 76.5; 74.2; 69.9; 60.8. EI-MS: 286 (100,  $[M - Glc]^+$ ), 229 (11), 184, 153 (7), 121 (26).

Eugenylglucoside. Colorless powder. M.p. 130–131°. IR (KBr): 3382, 1514, 1266, 1225, 1077, 1031. <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 6.97 (*d*,  $J = 8.7$ , 1 H); 6.78 (*d*,  $J = 2.0$ , 1 H); 6.64 (*dd*,  $J = 2.0$ , 8.2, 1 H); 5.91 (*ddt*,  $J = 6.7$ , 10.1, 16.8, 1 H); 5.04 (*dd*,  $J = 1.9$ , 17.0, 1 H); 5.01 (*dd*,  $J = 1.9$ , 9.8, 1 H); 4.82 (*d*,  $J = 7.4$ , 1 H); 3.72 (*s*, MeO); 3.64 (*dd*,  $J = 1.8$ , 11.8, 1 H); 3.42 (*dd*,  $J = 5.2$ , 11.8, 1 H); 3.27 (*d*,  $J = 6.7$ , 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 148.9; 144.9; 137.8; 133.5; 120.3; 115.6; 115.4; 113.0; 100.3; 76.9; 76.7; 73.2; 69.7; 60.6; 55.7; 39.0. EI-MS: 326 ( $M^+$ ), 164 (100,  $[M - Glc]^+$ ), 149, 133, 121, 103, 91, 73, 57.

Lupa-12,20(29)-dien-3 $\beta$ -ol. Colorless powder. IR (KBr): 3450, 2980, 1635, 1450, 1380, 1270, 1100, 1080, 1030, 770. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 5.12 (*t*,  $J = 3.5$ , 1 H); 4.67 (*br. d*,  $J = 2.0$ , 1 H); 4.56 (*br. d*,  $J = 2.0$ , 1 H); 3.25 (*dd*,  $J = 5$ , 12, 1 H); 1.68 (*s*, Me); 1.05 (*s*, Me); 0.96 (*s*, 2 Me); 0.82 (*s*, Me); 0.78 (*s*, Me); 0.75 (*s*, Me). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 150.9; 145.2; 121.7; 109.3; 78.8; 55.3; 50.4; 48.2; 47.9; 43.0; 42.8; 40.8; 40.0; 38.8; 38.7; 37.1; 35.5; 34.2; 27.4; 27.4; 20.9; 18.3; 29.8; 28.0; 19.3; 18.0; 16.1; 15.9; 15.4; 14.5. EI-MS: 424 (5,  $M^+$ ), 216 (24), 201 (18), 190 (20), 189 (95), 175 (58).

18 $\alpha$ H-Ursa-12,20(30)-dien-3 $\alpha$ -ol. Colorless needles. M.p. 163–165°. IR (KBr): 3395, 2905, 1590, 1460, 1390, 1025, 870. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 5.20 (*m*, 1 H); 4.65 (*br. s*, 2 H); 3.42 (*dd*,  $J = 2.5$ , 5.0, 1 H); 2.20 (*d*,  $J = 5.5$ , 1 H); 1.30 (*s*, Me); 1.13 (*s*, Me); 0.97 (*s*, Me); 0.90 (*d*,  $J = 6.0$ , Me); 0.83 (*s*, Me); 0.76 (*br. s*, 2 Me). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 156.9; 139.6; 124.5; 105.9; 79.0; 55.4; 50.5; 48.7; 42.0; 40.9; 39.4; 38.9; 38.8; 38.3; 37.1; 34.5; 34.1; 28.0; 27.4; 26.6; 25.6; 25.5; 21.4; 19.5; 18.3; 16.8; 15.9; 15.4; 14.8. EI-MS: 424 (23,  $M^+$ ), 216 (85), 207 (73), 202 (23), 189 (33), 187 (74), 95 (100).

*trans-Phytol*. Colorless oil. IR (KBr): 3340, 1668. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 5.40 (*t*, *J* = 6.8, 1 H); 4.15 (*d*, *J* = 6.8, 2 H); 1.98 (*t*, *J* = 6.8, 2 H); 1.66 (*s*, Me). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 140.3; 123.1; 59.4; 39.9; 16.1. EI-MS (70 eV): 296 (*M*<sup>+</sup>), 278 (*[M – H<sub>2</sub>O]*<sup>+</sup>), 71 (100).

*Lariciresinol 9-O-β-Glucoside*. Colorless, amorphous powder.  $[\alpha]_D^{20} = -38.8$  (*c* = 0.50, MeOH). UV (MeOH): 231 (3.97), 283 (3.57). IR (KBr): 3400, 2920, 1650, 1500, 1440, 1355, 1265, 1150, 1070, 1025, 820. <sup>1</sup>H-NMR (400 MHz, (D<sub>6</sub>)DMSO): 6.85 (*br. s*, 1 H); 6.77 (*br. s*, 1 H); 6.70 (*br. s*, 2 H); 6.65 (*d*, *J* = 8.0, 1 H); 6.54 (*d*, *J* = 8.0, 1 H); 5.08 (*d*, *J* = 4.8, 1 H); 4.98 (*d*, *J* = 5.2, 1 H); 4.19 (*t*, *J* = 7.2, 1 H); 4.13 (*dd*, *J* = 11.2, 7.2, 1 H); 4.04 (*dd*, *J* = 7.6, 7.2, 1 H); 4.00 (*dd*, *J* = 7.6, 7.2, 1 H); 3.75 (*s*, 2 MeO); 3.18 (*dd*, *J* = 12.4, 4.8, 1 H); 2.95–2.98 (*m*, 1 H); 2.82–2.89 (*m*, 1 H); 2.56 (*t*, *J* = 12.4, 1 H). <sup>13</sup>C-NMR (100 MHz, (D<sub>6</sub>)DMSO): 147.5; 147.4; 145.7; 144.5; 134.0; 131.8; 120.8; 118.4; 115.3; 115.0; 113.0; 110.3; 103.2; 81.2; 76.6; 76.5; 73.3; 71.4; 69.8; 66.2; 60.8; 55.4; 49.8; 41.9; 32.0. FAB-MS: 545 (*[M + Na]*<sup>+</sup>), 522 (*M*<sup>+</sup>), 359 (*[M – Glc]*<sup>+</sup>), 237, 219.

*9-Hydroxyguaiaimonoeoxygnan-9-O-β-D-glucoside*. Colorless syrup.  $[\alpha]_D^{20} = -4.1$  (*c* = 0.4, MeOH). The IR, UV, NMR, and MS data were basically identical with those of lariciresinol 9-O-β-glucoside. The relative configuration could not be unequivocally established.

*Stigmast-5-ene-3β,7α-diol*. Colorless needles (acetone). M.p. 202–204°. IR (KBr): 3605, 3400, 2950, 2935, 2860, 1665, 1464, 1380, 1228, 1192, 1111, 1057, 1010, 952, 928, 892. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 5.62 (*d*, *J* = 4.8, 1 H); 3.86 (*m*, 1 H); 3.59 (*m*, 1 H); 1.01 (*s*, 1 H); 0.94 (*d*, *J* = 6.6, 1 H); 0.83 (*d*, *J* = 6.6, 1 H); 0.81 (*d*, *J* = 6.6, 1 H); 0.70 (*s*, 1 H). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 143.9; 123.9; 71.4; 63.4; 55.7; 49.4; 45.8; 42.3; 42.2; 42.0; 39.2; 37.5; 37.4; 37.0; 36.0; 33.9; 31.4; 29.1; 28.1; 26.0; 25.9; 23.1; 20.8; 19.8; 19.2; 18.7; 18.3; 12.0; 11.6. EI-MS: 430 (3, *M*<sup>+</sup>), 412 (100).

*Stigmast-4-en-3-one*. Colorless needles (hexane). M.p. 87–89°. UV (CHCl<sub>3</sub>): 246 (4.20). IR (KBr): 2926, 2856, 1677, 1621, 1469, 1392. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 5.74 (*d*, *J* = 2.0, 1 H); 1.19 (*s*, 1 H); 0.93 (*d*, *J* = 6.6, 1 H); 0.85 (*t*, *J* = 7.2, 1 H); 0.84 (*d*, *J* = 6.8, 1 H); 0.82 (*d*, *J* = 6.8, 1 H); 0.72 (*s*, 1 H). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 199.5; 171.6; 123.7; 56.0; 55.9; 53.8; 45.8; 42.4; 39.6; 38.6; 36.0; 35.8; 35.7; 34.1; 33.9; 32.8; 32.1; 29.11; 28.1; 26.0; 24.1; 23.1; 21.0; 19.8; 19.2; 18.7; 17.4; 12.0; 11.9. EI-MS: 412 (100, *M*<sup>+</sup>), 370 (8), 289 (12), 271 (10), 229 (31), 147 (29), 124 (93).

*Stigmastane-3,6-dione*. Colorless crystals (acetone). M.p. 202–204°. IR (KBr): 1707, 1461, 1425, 1384, 1259, 1239. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 0.96 (*s*, 1 H); 0.93 (*d*, *J* = 6.4, 1 H); 0.85 (*t*, *J* = 6.9, 1 H), 0.84 (*d*, *J* = 6.0, 1 H); 0.82 (*d*, *J* = 6.6, 1 H); 0.70 (*s*, 1 H). <sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>): 211.2; 209.0; 57.5; 56.6; 56.0; 53.5; 46.6; 45.8; 43.0; 41.2; 39.4; 38.1; 38.1; 37.4; 37.0; 36.0; 33.8; 29.1; 28.1; 26.0; 24.0; 23.0; 21.6; 19.8; 19.0; 18.7; 12.5; 12.0; 11.9. EI-MS: 428 (100, *M*<sup>+</sup>), 287, 245, 231, 217, 175, 149, 137, 123, 109, 95, 81, 69, 55, 43.

*β-Sitosterol*. Colorless needles (acetone). M.p. 139–140°. The TLC and the IR data were identical with those of an authentic sample.

*β-Sitosterol-3-(6'-glyceryl)-D-glucopyranoside*. Colorless wax. IR (KBr): 3417, 2927, 2854, 1740, 1466, 1379, 1174, 1083, 1021, 723. The <sup>1</sup>H- and <sup>13</sup>C-NMR data were identical to those reported. in [15][17].

## REFERENCES

- [1] Z. H. Wu, Y. S. Chen, H. W. Liang, L. L. Wei, *Acta Bot. Boreal. Occident. Sin.* **1999**, *5*, 59.
- [2] J. Ma, Y. P. Shi, *J. Gansu Sci.* **2003**, *15*(2), 31.
- [3] H. J. Kim, E. R. Woo, H. Park, *J. Nat. Prod.* **1994**, *57*, 581.
- [4] A. Mulkens, I. Kapetanidis, *J. Nat. Prod.* **1988**, *51*, 496.
- [5] G. C. Levy, G. L. Nelson, 'Carbon-13 Nuclear Magnetic Resonance for Organic Chemists', J. Wiley & Sons, New York, 1972, Chapt. 4.
- [6] T. Fujita, M. Nakayama, *Phytochemistry* **1992**, *31*, 3265.
- [7] T. Fujita, A. Funayoshi, M. Nakayama, *Phytochemistry* **1994**, *37*, 543.
- [8] S. B. Mahato, A. P. Kundu, *Phytochemistry* **1994**, *37*, 1517.
- [9] A. Ulubelen, S. Öksüz, E. Tuzlacı, *Planta Med.* **1989**, *55*, 3.
- [10] D. K. Gupta, M. Ali, K. K. Bhutani, *Indian J. Chem., Sect. B* **1996**, *35*, 1079.
- [11] G. D. Brown, *Phytochemistry* **1994**, *36*, 1553.

- [12] T. Aoki, K. Takagi, T. Hirata, T. Suga, *Phytochemistry* **1982**, 21, 1361.
- [13] T. Satake, T. Murakami, Y. Saiki, C. M. Chen, *Chem. Pharm. Bull.* **1978**, 26, 1619.
- [14] T. Yoshihara, K. Yamaguchi, S. Sakamura, *Agric. Biol. Chem.* **1982**, 46, 853.
- [15] J. Tian, H. D. Sun, *Nat. Prod. Res Dev.* **1999**, 11, 1.
- [16] Y. P. Jin, Y. P. Shi, *Pharmazie* **2004**, 59, 885.
- [17] B. Achair, S. Crakrabarty, S. C. Pakrashi, *Phytochemistry* **1981**, 20, 1444.
- [18] Y. P. Shi, Z. J. Jia, *Indian J. Chem., Sect. B* **1997**, 36, 1038.
- [19] K. R. Markham, T. Ternal, R. Stanley, *Tetrahedron* **1978**, 34, 1389.
- [20] F. Abe, T. Yamauchi, *Chem. Phram. Bull.* **1987**, 35, 4661.
- [21] H. Y. Gong, 'Carbon-13 of Natural Organic Compounds', Yunnan Science & Technology Press, Yunnan, 1986, p. 299.

Received January 9, 2007